Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£128.23
|
196.55%
|
£207,587.87
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£128.23
|
177.98%
|
£194,582.69
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£7.35
|
96.52%
|
£137,566.84
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£359.50
|
6.96%
|
£74,873.55
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£1,964.00
|
-3.06%
|
£67,857.85
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£145.79
|
-10.46%
|
£62,678.41
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£145.79
|
-13.27%
|
£60,709.69
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.98
|
-44.18%
|
£39,074.33
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.